Прогнозування перебігу та ефективності вторинної профілактики гіпертонічної хвороби у мешканців Поділля шляхом розвитку концепції гіпертензивного серця, з урахуванням поліморфізму гену рецепторів ангіотензину-ІІ першого типу

162. Opposite Predictive Value of Pulse Pressure and Aortic

163. Pulse Wave Velocity on Heart Failure With Reduced Left

164. Ventricular Ejection Fraction

165. Insights From an Eplerenone Post-Acute Myocardial Infarction Heart

166. Failure Efficacy and Survival Study (EPHESUS) Substudy / V. Regnault, J. Lagrange, A. Pizard [et al.] // Hypertension. - 2014. - Vol.63. - P.105-111.

167. Pauca A.L. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform / A.L. Pauca, M.F. O'Rourke, N.D. Kon // Hypertension. - 2001. - Vol.38. - P. 932-937.

168. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study / B. Dahlof, P. Gosse, O. Gueret [et al.] // J. Hypertension. - 2005. - Vol.23(11). - P. 2063-2070.

169. Pfeffer M.A. Ventricular remodeling and reduced survival after myocardial infarction / M.A. Pfeffer, J.M. Pfeffer // Circulation. - 1987. - Vol.75. - P.IV93-IV97.

170. Pokharel P., Bella J.N. Regression of left ventricular hypertrophy: Lessons from clinical trials / P. Pokharel, J.N. Bella // OA Evidence-Based Medicine. - 2013. - Vol.30;1(2):13.

171. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial / L. Kurland, H. Melhus, J. Karlsson [et al.] // J. Hypertens. - 2002. - Vol. 20. - P.657-663.

172. Prevalence of obesity in Greek hypertensives / A.D. Eustratopopoulos, S.M. Voyaki, H. Lydakis [et al.] // J Hum Hypertension. - 1996. - Vol.10. - Suppl.3. - P.65-70

173. Prisant L.M. Hypertensive heart disease / L.M. Prisant // J. Clin. Hypertens. 2005. - Vol. 7 (4). - P. 231-238.

174. Prognosis of inappropriate left ventricular mass in hypertension. The MAVI study / G. De Simone, P. Verdecchia, S. Pede [et al.] // Hypertension. - 2002. - Vol.40. - P.470-476.

175. Prognostic value of electrocardiographic criteria for left ventricular hypertrophy / P. Bill, M.D. Hsieh,, X. Michael [et al.] // Am. Heart J. - 2005. - N.1. - P.161-165.

176. Pulse wave velocity and augmentation index, but not intima-media thickness, are early indicators of vascular damage hypercholesterolemic children / S. Riggio, G. Mandraffino, M.A. Sardo [et al.] // Europian Journal of Clinical Investigation. - 2010. - Vol. 40(3). - P.250-257.

177. Rabkin S. W. Correlation of pulse wave velocity with left ventricular mass in patients with hypertension once blood pressure has been normalized / S. W. Rabkin, S. H. Chan // Heart International. - 2012. - Vol.7. - P.27-31.

178. Ranasinghe P. The influence of family history of Hypertension on disease prevalence and associated metabolic risk factors among Sri Lankan adults / P. Ranasinghe, D. N. Cooray, R. Jayawardena, P. Katulanda // BMC Public Health. - 2015. - Vol. 15. - P.576-585.

179. Recommendations for Blood Pressure Measurement in Humans and Experimental Animals / T.G. Pickering, J.E. Hall, L.J. Appel [et al.] //Circulation. - 2005. - 111. - P.697-716.

180. Redon J. on behalf of POLPRI investigators. Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients / J. Redon, M. Luque-Otero, M. Martel, F.J. Chaves // Pharmacogenomics J. - 2005. - Vol.5. - P.14-20.

181. Regression of left ventricular hypertrophy and microalbuminuria changes during antihypertensive treatment / E. Rodilla, J.M. Pascual, J.A. Costa [et al.]// J. Hypertens. - 2013. - Vol.31(8). - P.1683-1691.

182. Relation of Left Ventricular Mass and Geometry to Morbidity and Mortality in Uncomplicated Essential Hypertension / M.J. Koren, R.B. Devereux, P.N. Casale [et al.] // Annals of Internal Medicine. - Vol. 114. - N.5. - P.345-352.

183. Relations Between Aortic Stiffness and Left Ventricular Structure and Function in Older Participants in the Age, Gene/Environment Susceptibility-Reykjavik Study / V. Bell, S. Siggurdson, J.J.M. Westenberg [et al.] // Circ. Cardiovasc. Imaging. - 2015. - Vol.8. - e003039.

184. Relationship of 24-hour blood pressure mean and variability to severity of target organ damage in hypertension / G. Parati, G. Pomidossi, F. Albini, [et al.] // J. Hypertens. - 1987. - Vol.5. - P.93-98.

185. Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes / Ц. Bozkurt, A. De Boer, D.E. Grobbee [et al.] // Journal of Renin-Angiotensin-Aldosterone System. - 2009. - Vol. 10(2). - P.101-108.

186. Role of left ventricular regional nonuniformity in hypertensive diastolic dysfunction / Y. Nakashima, T. Nii, M. Ikeda, K. Arakawa // J.Am. Coll. Cardiol. - 1993. - Vol.22. - P.790-795.

187. Saavedra J.M. Studies on genes and hypertension: a daunting task / J.M. Saavedra // J. Hypertens. - 2005. - Vol.23. - P.929-932.

188. Saito T. A quantative evaluation of the effects of sex and age on the positivity of family history of hypertension / T. Saito, I. Saito, S. Nanri, T. Furukawa // Journal of Epidemiology. - 1998. - Vol.8 (2). - P.99-105.

189. Schelleman H. Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or в-blocker use and the risk of myocardial infarction and stroke / H. Schelleman, O.H. Klungel, J.C. Witteman [et al.] // Pharmacogenomics J. - 2008. - Vol.8. - P.400-407.

190. Schirmer H. Prevalence of left ventricular hypertrophy in a general population The Tromso Study / H. Schirmer, P. Lunde, K. Rasmussen // European Heart Journal. - 1999. - Vol. 20. - P.429-438.

191. Schwartz F. Mitochondrial genome mutations in hypertensive individuals / F. Schwartz, A. Duka, F. Sun // Am. J. Hypertens. - 2004. - Vol.17. - P.629-635.

192. Sex-Specific Determinants of Left Ventricular Mass in Pre-Diabetic and Type 2 Diabetic Subjects. The Augsburg Diabetes Family Study / B. Kuch, W. von Scheidt, W. Peter [et al.] // Diabetes Care. - 2007. - Vol. 30. - P.946 -952.

193. Sharman J.E. Augmentation index, left ventricular contractility and wave reflection / J.E. Sharman, J.E. Davies, C. Jenkins, T.H. Marwick // Hypertension. - 2009. - Vol.54 (5). - P.1099-1105.

194. Sharman J.E. Randomized Trial of Guiding Hypertension Management

195. Using Central Aortic Blood Pressure Compared With

196. Best-Practice Care

197. Principal Findings of the BP GUIDE Study / J.E. Sharman, T.H. Marwick, D. Gilroy [et al.] // Hypertension. - 2013. - Vol.62. - P.1138-1145.

198. Siest G. Enzymes and pharmacogenetics of cardiovascular drugs / G. Siest, E. Jeannesson, S. Visvikis-Siest // Clin. Chim. Acta. - 2007. - Vol.381. - P.26-31.

199. Singh M. Molecular genetics of essential hypertension / M. Singh, A.K. Singh, P. Pandey, S. Chandra, K.A. Singh, I.S. Gambhir // Clinical and experimental hypertension. - 2016. - Vol.38 (3). - P.268-277.

200. Slama M. Diastolic dysfunction in hypertension / M. Slama, D. Susik, J. Varagic, E.D. Frohlich // Cur. Opin. Cardiol. - 2002. - Vol.17(4). - P.368-373.

201. Sohn D.W. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function / D.W. Sohn, I.H. Chai, D.J. Lee [et al.] // J. Am. Coll. Cardiol. - 1997. - Vol. 30(2). - P.474-480.

202. Spiering W. Angiotensin II Sensitivity Is Associated With the Angiotensin II Type 1 Receptor A1166C Polymorphism in Essential Hypertensives on a High Sodium Diet / W. Spiering, A.A. Kroon, M.M. Fuss-Lejeune // Hypertension. - 2000. - Vol.36. - P.411-416.

203. Stamler R. Family (parental) history and prevalence of hypertension. Results of a nationwide screening programm / R. Stamler, J. Stamler, W.F. Riedlinger [et al.] // JAMA. - 1979. - Vol.241(1). - P.43-46

204. Stankovic A. Angiotensin II type 1 receptor gene polymorphism and essential hypertension in Serbian population / A. Stankovic, M. Zivkovic, S. Glisic, D. Alavantich // Clinica Chimica Acta. - 2003. - Vol.327 (1-2). - P.181-185.

205. Stepien M. Evaluation of self-measurement of blood pressure in ambulatory monitoring of hypertension therapy / M. Stepien, A. Stepien, W. Matusewicz // Przeglad Lekarski. - 2002. - Vol.59 (9). - P.756-758.

206. Stergiou G.S. Self-monitoring of blood pressure at home: how many measurements are needed? / G.S. Stergiou, I.I. Skeva, A.S. Zourbaki, T.D. Mountokalakis // J. Hypertens. - 1998. - Vol. 16(6). - P.725-731.

207. Stoner L. Assessments of Arterial Stiffness and Endothelial Function Using Pulse Wave Analysis / L. Stoner, J.M. Young, S. Freyer // International Journal of Vascular Medicine. - Vol. 2012, Article ID 903107, 9 pages doi:10.1155/2012/903107

208. Sun F. A novel class of tests for the detection of mitochondrial DNA-mutation involvement in diseases / F. Sun, J. Cui, H. Gavras, F. Schwartz // Am. J.Hum. Genet. - 2003. - Vol. 72. - P. 1515-1526.

209. Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) Trial. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients / L. Kurland, H. Melhus, J. Karlsson [et al.] J. Hypertens. - 2001. - Vol.19. - P.1783-1787.

210. The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives / J. Diez, C. Laviades, J. Orbe [et al.] // J. Hypertens. _ 2003. - Vol. 21. - P. 2085-2092.

211. The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators. CAFE Steering Committee and Writing Committee. Differential Impact of Blood Pressure-Lowering Drugs on Central Aortic Pressure and Clinical Outcomes Principal Results of the Conduit Artery Function Evaluation (CAFE) Study / B. Williams, P.S. Lacy, S.M. Thom [et al.] // Circulation. - 2006. - Vol.113 (7). - P.1213-1225.

212. The genetic determaination of left venricular mass in healthy adults / L. Swan, D.H. Birnie, S. Padmanabhan [et al.]// Eur. Heart J. - 2003. - Vol. 24. - N6. - P. 577 - 582.

213. The Influence of Marital Adjustment on 3-Year Left Ventricular Mass and Ambulatory Blood Pressure in Mild Hypertension / B. Baker, M. Paquette, J. P. Szalai [et al.] // JAMA Internal Medicine. - 2000. - Vol. 160(22). - P. 3453-3458.

214. The prognostic legacy of left ventricular hypertrophy: cumulative evidence after the MAVI study / F. Angeli, G. Reboldi, C. Poltronieri [et al.] // Journal of Hypertension. - 2015. - Vol. 33 (11). - P.2322-2330.

215. The Reference Values for Arterial Stiffness Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: establishing normal and reference values. European Heart Journal. - 2010. - Volume 31(l9). - P. 2338-2350.

216. The relationship between blood pressure and left ventricular mass index depends on an excess adiposity / G.R. Norton, O.H. Majane, E. Libhaber [et al.] // J. Hypertension. - 2009. - Vol.27. - N9. - P.1873 - 1883.

217. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial / L. Kurland, P. Hallberg, H. Melhus [et al.]// Am. J. Hypertens. - 2008. - Vol.21. - P.836-839.

218. The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study / D.A. Bluemke, R.A. Kronmal, J.A. Lima [et al.] // J. Am. Coll. Cardiol. - 2008. - Vol.52. - P.2148-2155.

219. Thu H. Le; Hyung-Suk Kim; Andrew M. Allen; Robert F. Spurney; Oliver Smithies; Thomas M. Coffman Physiological Impact of Increased Expression of the AT1 Angiotensin Receptor Hypertension. 2003;42:507-514

220. Tozawa M. Family history of hypertension and blood pressure in screened cohort / M. Tozawa, S. Oshiro, C. Iseki, S. Sesoko [et al.] // Hypertension Research. - 2001. - Vol.24 (2). - P.93-98.

221. Trends in hypertension prevalence, awareness, treatment and control rates in the United States adults between 1988-1994 and 1999-2004 / J.A. Cutler, P.D. Sorlie, M. Woltz [et al.] // Hypertension. - 2008. - Vol.52. - P.818-827.

222. Turner S.T. Antihypertensive pharmacogenetics: getting the right drug into the right patient / S.T. Turner, G.L. Schwartz, A.B. Chapman, E. Boerwinkle // J. Hypertens. - 2001. - Vol.19. - P.1?11.

223. Turner S.T. C825T polymorphism of the G protein в(3)-subunit and antihypertensive response to a thiazide diuretic / S.T. Turner, G.L. Schwartz, A.B. Chapman, E. Boerwinkle // Hypertension. - 2001. - Vol.37. - P.739-743.

224. Turner S.T. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic / S.T. Turner, K.R. Bailey, B.L. Fridley [et al.] // Hypertension. - 2008.- Vol. 52. - P.359-365.

225. van den Borne S.W., Isobe S., Verjans J.W. et al. Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction / S.W. van den Borne, S. Isobe, J.W. Verjans [et al.] // J. Am. Coll. Cardiol. - 2008. - Vol.52. - P.2017-2028.

226. Van Den Hoogen J.P.H. Reproducibility of electrocardiographic criteria for left ventriculsr hypertrophy in hypertensive patients in general practice / J.P.H. Van Den Hoogen, W.H. Mol, A. Kowsoleea, J.W. Van Ree // Eur. Heart J. - 1992. - Vol.13 (12). - P.1606-1610.

227. Varagic J. AT1 receptor antagonism attenuates target organ effects of salt excess in SHRs without affecting pressure / J. Varagic, E.D. Frohlich, D. Susic [et al.] // Am. J. Physiol. Heart Circ. Physiol. - 2008. - Vol. 294. - P.853-858.

228. Verdecchia P. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension / P. Verdecchia, G. Schillaci, M. Guerrieri [et al.] // Circulation. - 1990. - Vol. 81. - P.528-536.

229. Vingerhoed N.M. Haemodynamic and pulse wave responses to intravenous infusions of angiotensin II during chronic telmisartan therapy in normal volunteers / N.M. Vingerhoed, R. Gilles, J.B. Howes // Journal of the Renin-Angiotensin Aldosterone System. - 2003. - Vol. 4(4). - P. 244 -248.

230. Visualisation of cell death in vivo in patients with acute myocardial infarction / L. Hofstra, I.H. Liem, E.A. Dumont [et al.] // Lancet. - 2000. - Vol. 356. - P.209 -212.

231. Vlachopoulos C. Genesis of the normal and abnormal arterial pulse / C. Vlachopoulos, M. O`Rourke // Cur. Probl. Cardiol. - 2000. - Vol.25 (5). - P.303-367.

232. Wang K.L. Wave reflection and arterial stiffness in the prediction of 15-year all-cause and cardiovascular mortalities: a community-based study / K.L. Wang, H.M. Cheng, S.H. Sung [et al.] // Hypertension. - 2010. - Vol.55 (3). P.799 - 805.

233. Weber K.T. Myocardial fibrosis: functional significance and regulatory factors / K.T. Weber, C.G. Brilla, J.S. Janicki // Cardiovasc. Res. - 1993. -Vol. 27. - P. 341-348.

234. Weber T. Pulse waveform characteristics predict cardiovascular events and mortality in patients undergoing coronary angiography / T. Weber, M. O`Rourke, E. Lassnig [et al.] // J.Hypertension. - 2010. - Vol.28 (4). - P.797-805.

235. Williams B. The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators. CAFE Steering Committee and Writing Committee: Differential Impact of Blood Pressure-Lowering Drugs on Central Aortic Pressure and Clinical Outcomes Principal Results of the Conduit Artery Function Evaluation (CAFE) Study / B. Williams, P.S. Lacy, S.M. Thom [et al.] // Circulation. - 2006. - Vol.113 (7). - P.1213-1225.

236. Wiysonge C.S. Beta-blockers for hypertension / C.S. Wiysonge, H. Bradley, B.M. Mayosi [et al.] // Cochrane Database Syst. Rev. - 2007. - Vol. 24 (1). - CD002003.

237. Wright G.M. First line drugs for hypertension / G.M. Wright, V.M. Musini // Cochrane Database Syst. Rev. - 2009. - Vol.8(3). - CD001841.

238. Wykrкtowicz M. Left Ventricular Mass: Correlation with Fatness, Hemodynamics and Renal Morphology / M. Wykrкtowicz, K. Katulska, A. Milewska, T. Krauze // Pol. J. Radiol. - 2014. - Vol.79. - P. 426-430

239. Yang Q. Maternal influence on blood pressure suggests involvement of mitochondrial DNA in the pathogenesis of hypertension: the Framingham Heart Study / Q. Yang, S.K. Kim, F. Sun, J. Cui // J. Hypertension. - 2007. - Vol.25 (10). - P.2067-2073.

240. Yasuno S. Clinical significance of left ventricular hypertrophy and changes in left ventricular mass in high-risk hypertensive patients: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan trial / S. Yasuno, K. Ueshima, K. Oba [et al.] // J. Hypertens. - 2009. - Vol. 27(8). P.1705-1712

241. Ybarra J. The influence of obesity duration on left ventricular mass, volume and function: A pilot study / J. Ybarra, J. H. Romeo, S. Fйrnandez, J. Sanchez-Hernandez // Health. - 2012. - Vol.4. - No12A. - P.1420-1427.

242. Yekeen L.A. Prevalence of obesity and high level cholesterol in hypertension: analysis of data from the university college hospital, Ibadan / L.A. Yekeen, R.A. Sanusi, A.U. Ketiku // African Journal of Biomedical Research. - 2003. - Vol.6. - P.129-132.

243. Zeviani M. Mitochondrial diseases / M. Zeviani, E. Bonilla, D.C. Devivo, S. Dimauro // Neurol. Clin. - 1989. - Vol. 7. - P.123-156.

244. Zhang N. Effects of angiotensin II type I receptor A1166C polymorphism on benazepril action in hypertensive patients: A family-based association study / N. Zhang, H. Cui, L. Yang // Arch. Pharm. Res. - 2012. - Vol.35(10). - P.1817-1822.

245. Zhu H. Mitochondrial mutations in essential hypertension / H. Zhu, S. Wang // Genetics and Pathophysiology of Essential Hypertension (ed. by prof. M.Khullar): Pub. InTech., 2012. - P.169-180.

246. Zhu H. Relationship between Nocturnal Blood Pressure and Left Ventricular Hypertrophy in Hypertensive Patients / H. Zhu, W. Zhang, Y. Shi [et al.] // J. Hypertens. - 2014. - Vol.3. - P.151.

247. в1- and в2-adrenergic receptor gene variation, в-blocker use and risk of myocardial infarction and stroke / R.N. Lemaitre, S.R. Heckbert, N. Sotoodehnia [et al.] // Am. J. Hypertens. - 2008. - Vol.21. - P.290-296.

248. в1-adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension / J. Liu, Z.Q. Liu, B.N. Yu [et al.] // Clin. Pharmacol. Ther. - 2006. - Vol.80. - P.23-32.

249. в2-adrenergic receptor genotype and survival among patients receiving в-blocker therapy after an acute coronary syndrome / D.E. Lanfear, P.G. Jones, S. Marsh [et al.] // JAMA. - 2005. - Vol.294. - P.1526-1533.

250. в-adrenergic receptor gene polymorphisms and в-blocker treatment outcomes in hypertension / M.A. Pacanowski, Y. Gong, R.M. Cooper-Dehoff [et al.] // Clin. Pharmacol. Ther. - 2008. - Vol.84. - P.715-721.

Размещено на Allbest.ru